Antibody and T-cell responses to SARS-CoV-2 vaccines in MS patients on Ocrelizumab and other disease-modifying therapies: preliminary results of an ongoing, prospective study

I. Kister,Y. Patskovsky, I. Voloshyna, N. Ferstler, R. Curtin,V. Yogambigai,S. Nyovanie,M. J. Mulligan,J. Kim, E. Tardio, Z. Rimler, K. Perdomo, T. Bacon,L. Zhovtis Ryerson, M. Samanovic-Golden, A. Cornelius, C. Raposo,J. Priest, R. Winger,M. Krogsgaard,G. J. Silverman

MULTIPLE SCLEROSIS JOURNAL(2021)

引用 1|浏览4
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要